Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: Anti-inflammatory effect of cholecystokinin

Diabetes

Volumn 61, Issue 4, 2012, Pages 897-907

  Miyamoto, Satoshi ^a   Shikata, Kenichi ^a,b   Miyasaka, Kyoko ^c   Okada, Shinichi ^a   Sasaki, Motofumi ^a   Kodera, Ryo ^a,b   Hirota, Daisho ^a   Kajitani, Nobuo ^a   Takatsuka, Tetsuharu ^a   Kataoka, Hitomi Usui ^a   Nishishita, Shingo ^a   Sato, Chikage ^a   Funakoshi, Akihiro ^d   Nishimori, Hisakazu ^a   Uchida, Haruhito Adam ^a   Ogawa, Daisuke ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c TOKYO KASEI UNIVERSITY   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHEMOTAXIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLOMERULUS; KIDNEY HYPERTROPHY; KIDNEY MASS; MACROPHAGE; MALE; MICROALBUMINURIA; MOUSE; NEPHRITIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; UPREGULATION; WILD TYPE;

ANIMALS; CHEMOTAXIS; CHOLECYSTOKININ; DIABETES MELLITUS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; NF-KAPPA B; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859534363     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0402     Document Type: Article

References (44)

1. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808 (Pubitemid 29521694)
2. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232 (Pubitemid 35463925)
3. Nelson CL, Karschimkus CS, Dragicevic G, et al. Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant 2005;20:2420-2426 (Pubitemid 41548866)
4. Sugimoto H, Shikata K, Hirata K, et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997;46:2075-2081 (Pubitemid 27512099)
5. Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003;52:2586-2593 (Pubitemid 37210549)
6. Jorpes E, Mutt V. Cholecystokinin and pancreozymin, one single hormone? Acta Physiol Scand 1966;66:196-202
7. Mutt V, Jorpes JE. Structure of porcine cholecystokinin-pancreozymin. 1. Cleavage with thrombin and with trypsin. Eur J Biochem 1968;6:156-162
8. Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 2006;86:805-847 (Pubitemid 44033383)
9. Rehfeld JF. Clinical endocrinology and metabolism. Cholecystokinin. Best Pract Res Clin Endocrinol Metab 2004;18:569-586
10. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994;15:731-755 (Pubitemid 24221851)
11. Meng AH, Ling YL, Zhang XP, Zhang JL. Anti-inflammatory effect of cholecystokinin and its signal transduction mechanism in endotoxic shock rat. World J Gastroenterol 2002;8:712-717
12. Li S, Ni Z, Cong B, et al. CCK-8 inhibits LPS-induced IL-1beta production in pulmonary interstitial macrophages by modulating PKA, p38, and NF-kappaB pathway. Shock 2007;27:678-686 (Pubitemid 46795130)
13. Bozkurt A, Cakir B, Ercan F, Yeǧen BC. Anti-inflammatory effects of leptin and cholecystokinin on acetic acid-induced colitis in rats: role of capsaicin-sensitive vagal afferent fibers. Regul Pept 2003;116:109-118 (Pubitemid 37355978)
14. Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 2005;202:1023-1029 (Pubitemid 41464495)
15. Sligh JE Jr, Ballantyne CM, Rich SS, et al. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1993;90:8529-8533 (Pubitemid 23277702)
16. Usui HK, Shikata K, Sasaki M, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. [Published erratum appears in Diabetes 2007; 56:897.] Diabetes 2007;56:363-372
17. Miyasaka K, Ichikawa M, Ohta M, et al. Energy metabolism and turnover are increased in mice lacking the cholecystokinin-B receptor. J Nutr 2002; 132:739-741 (Pubitemid 34275075)
18. Takiguchi S, Suzuki S, Sato Y, et al. Role of CCK-A receptor for pancreatic function in mice: a study in CCK-A receptor knockout mice. Pancreas 2002;24:276-283 (Pubitemid 34260653)
19. Nagata A, Ito M, Iwata N, et al. G protein-coupled cholecystokinin-B/ gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci USA 1996;93:11825-11830 (Pubitemid 26347208)
20. Asakura S, Hashimoto D, Takashima S, et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest 2010;120:2370-2378
21. Nishimori H, Maeda Y, Teshima T, et al. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by downregulating Th1 and Th17. Blood 2012;119:285-295
22. Uchida HA, Poduri A, Subramanian V, Cassis LA, Daugherty A. Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2011;31:2845-2852
23. Fong JS, Drummond KN. Method for preparation of glomeruli for metabolic studies. J Lab Clin Med 1968;71:1034-1039
24. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-978
25. Wågsäter D, Zhu C, Björck HM, Eriksson P. Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis 2009;202:415-423
26. Gómez-Garre D, Muñoz-Pacheco P, González-Rubio ML, Aragoncillo P, Granados R, Fernández-Cruz A. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009;156:1218-1227
27. Wank SA, Harkins R, Jensen RT, Shapira H, de Weerth A, Slattery T. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 1992;89:3125-3129
28. Kopin AS, Lee YM, McBride EW, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992;89:3605-3609
29. Lacourse KA, Lay JM, Swanberg LJ, Jenkins C, Samuelson LC. Molecular structure of the mouse CCK-A receptor gene. Biochem Biophys Res Commun 1997;236:630-635 (Pubitemid 27384678)
30. Galindo J, Jones N, Powell GL, Hollingsworth SJ, Shankley N. Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreas. Pancreas 2005;31:325-331 (Pubitemid 41566880)
31. von Schrenck T, Ahrens M, de Weerth A, et al. CCKB/gastrin receptors mediate changes in sodium and potassium absorption in the isolated perfused rat kidney. Kidney Int 2000;58:995-1003
32. de Weerth A, Jonas L, Schade R, et al. Gastrin/cholecystokinin type B receptors in the kidney: molecular, pharmacological, functional characterization, and localization. Eur J Clin Invest 1998;28:592-601 (Pubitemid 28350026)
33. Lay JM, Jenkins C, Friis-Hansen L, Samuelson LC. Structure and developmental expression of the mouse CCK-B receptor gene. Biochem Biophys Res Commun 2000;272:837-842 (Pubitemid 30420723)
34. Sacerdote P, Wiedermann CJ, Wahl LM, Pert CB, Ruff MR. Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. Peptides 1991;12:167-176
35. Xu SJ, Gao WJ, Cong B, Yao YX, Gu ZY. Effect of lipopolysaccharide on expression and characterization of cholecystokinin receptors in rat pulmonary interstitial macrophages. Acta Pharmacol Sin 2004;25:1347-1353 (Pubitemid 39361808)
36. Sanchez AP, Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 2009;11:e13
37. Lee FT, Cao Z, Long DM, et al. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004;15:2139-2151 (Pubitemid 39031352)
38. Nam JS, Cho MH, Lee GT, et al. The activation of NF-kappaB and AP-1 in peripheral blood mononuclear cells isolated from patients with diabetic nephropathy. Diabetes Res Clin Pract 2008;81:25-32
39. Hofmann MA, Schiekofer S, Isermann B, et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 1999;42:222-232 (Pubitemid 29064245)
40. Guha M, Bai W, Nadler JL, Natarajan R. Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways. J Biol Chem 2000;275:17728-17739 (Pubitemid 30430822)
41. Takano Y, Yamauchi K, Hayakawa K, et al. Transcriptional suppression of nephrin in podocytes by macrophages: roles of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett 2007;581:421-426 (Pubitemid 46149613)
42. Aunapuu M, Roosaar P, Järveots T, et al. Altered renal morphology in transgenic mice with cholecystokinin overexpression. Transgenic Res 2008;17:1079-1089
43. Lay JM, Gillespie PJ, Samuelson LC. Murine prenatal expression of cholecystokinin in neural crest, enteric neurons, and enteroendocrine cells. Dev Dyn 1999;216:190-200 (Pubitemid 29471181)
44. León-Tamariz F, Verbaeys I, Van Boven M, et al. Biodistribution and pharmacokinetics of PEG-10kDa-cholecystokinin-10 in rats after different routes of administration. Curr Drug Deliv 2010;7:137-143